Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gut Microbiota and Silybin Response in NASH
ChiCTR2500104129Phase 4Not yet recruiting
- Sponsor
- Xiangya Hospital, Central South University
- Start
- Jun 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of silibinin in metabolic dysfunction-associated steatohepatitis (MASH) (2 arms), sponsored by Xiangya Hospital, Central South University. Primary endpoints: Liver function and Gut microbial DNA. Planned start Jun 2025; status: not yet recruiting.
02
Drugs
silibinin
03
Conditions
metabolic dysfunction-associated steatohepatitis (MASH)
Beyond the preview
Go deeper on ChiCTR2500104129.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500104129.